Introgen: Advexin gets orphan status in European Union to treat Li-Fraumeni syndrome

By E. Janene Geiss

Philadelphia, Sept. 7 - Introgen Therapeutics, Inc. said Thursday that its Stockholm subsidiary Gendux was notified by the European Medicines Agency Committee for Orphan Medicinal Products that Advexin p53 therapy has received Orphan Medicinal Product Designation in Europe for the treatment of Li-Fraumeni syndrome.

Li-Fraumeni Syndrome is a genetic disorder characterized by inherited mutations in the p53 tumor suppressor gene, the Austin, Texas, biotechnology company said in a news release. The disease greatly increases the risk of developing several types of cancer at a young age.

Previously reported positive clinical findings demonstrated the utility of Advexin p53 therapy in Li-Fraumeni cancer. Introgen has said it is making Advexin p53 therapy available on a compassionate-use basis to qualified Li-Fraumeni syndrome patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.